Conjugation of polysaccharide 6B from Streptococcus pneumoniae with pneumococcal surface protein A: PspA conformation and its effect on the immune response

Clinical and Vaccine Immunology

Volumn 20, Issue 6, 2013, Pages 818-826

  Perciani, Catia T ^a,b   Barazzone, Giovana C ^a   Goulart, Cibelly ^a   Carvalho, Eneas ^a   Cabrera Crespo, Joaquin ^a   Gonçalves, Viviane M ^a   Leite, Luciana C C ^a   Tanizaki, Martha M ^a  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4,6 DIMETHOXY 1,3,5 TRIAZIN 2 YL) 4 METHYL MORPHOLINIUM CHLORIDE; AMIDE; AMINE; CARBOXYL GROUP; COMPLEMENT; IMMUNOGLOBULIN G; OUTER SURFACE PROTEIN A; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS POLYSACCHARIDE 6B; SODIUM CHLORIDE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; PNEUMOCOCCAL SURFACE PROTEIN A; PNEUMOCOCCUS VACCINE; RECOMBINANT VACCINE; VACCINE;

ALPHA HELIX; AMINATION; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CHEMICAL REACTION; CIRCULAR DICHROISM; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG STRUCTURE; FEMALE; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; STREPTOCOCCUS PNEUMONIAE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; COMPARATIVE STUDY; HUMAN; IMMUNOLOGY;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CIRCULAR DICHROISM; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; PROTEIN CONFORMATION; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE; VACCINES, SYNTHETIC;

EID: 84891378125     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00754-12     Document Type: Article

References (52)

1. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. 2009 Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374:893-902.
2. Linares J, Ardanuy C, Pallares R, Fenoll A. 2010. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin. Microbiol. Infect. 16:402-410.
3. Fedson DS, Nicolas-Spony L, Klemets P, van der Linden M, Marques A, Salleras L, Samson SI. 2011. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev. Vaccines 10:1143-1167.
4. Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M. 2001. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 19:4780-4790. (Pubitemid 32800764)
5. Griffioen AW, Rijkers GT, Janssens-Korpela P, Zegers BJ. 1991. Pneumococcal polysaccharides complexed with C3d bind to human B lymphocytes via complement receptor type 2. Infect. Immun. 59:1839-1845.
6. Timens W, Boes A, Rozeboom-Uiterwijk T, Poppema S. 1989. Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response. J. Immunol. 143:3200-3206. (Pubitemid 20010145)
7. Guttormsen HK, Sharpe AH, Chandraker AK, Brigtsen AK, Sayegh MH, Kasper DL. 1999. Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines. Infect. Immun. 67:6375-6384.
8. Redelings MD, Sorvillo F, Simon P, Mascola L. 2005. Declining early childhood mortality from invasive pneumococcal disease: the impact of vaccination. Arch. Pediatr. Adolesc. Med. 159:195-196. (Pubitemid 40194190)
9. Roush SW, Murphy TV. 2007. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 298:2155-2163. (Pubitemid 350106654)
10. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. 2009. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin. Infect. Dis. 49:205-212.
11. Ruckinger S, van der Linden M, Reinert RR, von Kries R, Burckhardt F, Siedler A. 2009. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 27:4136-4141.
12. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. 2007. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a timeseries analysis. Lancet 369:1179-1186. (Pubitemid 46527876)
13. Chibuk TK, Robinson JL, Hartfield DS. 2010. Pediatric complicated pneumonia and pneumococcal serotype replacement: trends in hospitalized children pre and post introduction of routine vaccination with pneumococcal conjugate vaccine (PCV7). Eur. J. Pediatr. 169:1123-1128.
14. Leach AJ, Morris PS, McCallum GB, Wilson CA, Stubbs L, Beissbarth J, Jacups S, Hare K, Smith-Vaughan HC. 2009. Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001. BMC Infect. Dis. 9:121. doi:10.1186/1471-2334-9-121.
15. Munoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. 2008. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin. Infect. Dis. 46:174-182. (Pubitemid 351269154)
16. Borrow R, Dagan R, Zepp F, Hallander H, Poolman J. 2011. Glycoconjugate vaccines and immunointeractions and implication for vaccination schedules. Expert Rev. Vaccines 10:1621-1631.
17. Dagan R, Poolman J, Siegrist CA. 2010. Glycoconjugate vaccines and immune interference: a review. Vaccine 28:5513-5523.
18. Ren B, Szalai AJ, Thomas O, Hollingshead SK, Briles DE. 2003. Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect. Immun. 71:75-85. (Pubitemid 36026006)
19. Tu AH, Fulgham RL, McCrory MA, Briles DE, Szalai AJ. 1999. Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect. Immun. 67:4720-4724. (Pubitemid 29400455)
20. Shaper M, Hollingshead SK, Benjamin WH, Jr, Briles DE. 2004. PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected]. Infect. Immun. 72:5031-5040. (Pubitemid 39223387)
21. Briles DE, Hollingshead SK, King J, Swift A, Braun PA, Park MK, Ferguson LM, Nahm MH, Nabors GS. 2000. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J. Infect. Dis. 182:1694-1701.
22. Wu HY, Nahm MH, Guo Y, Russell MW, Briles DE. 1997. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J. Infect. Dis. 175:839-846. (Pubitemid 27142957)
23. Crain MJ, Waltman WD, II, Turner JS, Yother J, Talkington DF, McDaniel LS, Gray BM, Briles DE. 1990. Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect. Immun. 58:3293-3299. (Pubitemid 20293438)
24. Hollingshead SK, Becker R, Briles DE. 2000. Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect. Immun. 68:5889-5900.
25. Hollingshead SK, Baril L, Ferro S, King J, Coan P, Briles DE. 2006. Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries. J. Med. Microbiol. 55:215-221. (Pubitemid 43201750)
26. Pimenta FC, Ribeiro-Dias F, Brandileone MC, Miyaji EN, Leite LC, Sgambatti de Andrade AL. 2006. Genetic diversity of PspA types among nasopharyngeal isolates collected during an ongoing surveillance study of children in Brazil. J. Clin. Microbiol. 44:2838-2843. (Pubitemid 44228578)
27. Santamaria R, Goulart C, Perciani CT, Barazzone GC, Carvalho R, Goncalves VM, Leite LC, Tanizaki MM. 2011. Humoral immune response of a pneumococcal conjugate vaccine: capsular polysaccharide serotype 14-lysine modified PspA. Vaccine 29:8689-8695.
28. Barazzone GC, Perciani CT, Raw I, Tanizaki MM. July 2011. Método de conjugação de polissacarídeo capsular a uma proteína carregadora, para uso como antígeno vacinal contra bactérias encapsuladas, utilizando o reagente cloreto de 4-(4,6-dimetoxi-1,3,5-triazin-2-il)-4-metilmorfolino (DMT-MM). Brazilian patent PI0904528-7.
29. Barazzone GC, Carvalho RJ, Kraschowetz S, Horta ACL, Sargo C, Silva AJ, Tanizaki MM, Cabrera-Crespo J, Gonçalves VM. 2011. Production and purification of recombinant fragment of pneumococcal surface protein A (PspA) in Escherichia coli. Proc. Vaccinol. 4:27-35.
30. Carvalho RJ, Cabrera-Crespo J, Tanizaki MM, Gonçalves VM. 2012. Development of production and purification processes of recombinant fragment of pneumococcal surface protein A in Escherichia coli using different carbon sources and chromatography sequences. Appl. Microbiol. Biotechnol. 94:683-694.
31. Silva M, Cabrera-Crespo J, Sbrogio-Almeida ME, Miyaji EN, Ho PL, Leite LC, Lopes AP. 2007. Optimizing expression of Streptococcus pneumoniae surface protein a, PspA: serocross-reactivity within families of antisera induced against clades 1 and 3. Mol. Biotechnol. 37:146-154. (Pubitemid 350135891)
32. Gonçalves VM, Takagi M, Carmo TS, Albani SMF, Pinto JV, Zangirolami TC, Giordano RC, Tanizaki MM, Cabrera-Crespo J. 2007. Simple and efficient method of bacterial polysaccharides purification for vaccines production using hydrolytic enzymes and tangential flow ultrafiltration, p 250-257. In Mendez-Vilas A (ed), Communicating current research and educational topics and trends in applied microbiology. Formatex, Badajoz, Spain.
33. Tyllianakis PE, Kakabakos SE, Evangelatos GP, Ithakissios DS. 1994. Direct colorimetric determination of solid-supported functional groups and ligands using bicinchoninic acid. Anal. Biochem. 219:335-340. (Pubitemid 24206813)
34. Qi XY, Keyhani NO, Lee YC. 1988. Spectrophotometric determination of hydrazine, hydrazides, and their mixtures with trinitrobenzenesulfonic acid. Anal. Biochem. 175:139-144.
35. Dubois M, Gilles KA, Hamilton JK, Rebers PA, Smith F. 1956. Colorimetric method for determination of sugars and related substances. Anal. Chem. 28:350-356.
36. Fryer HJ, Davis GE, Manthorpe M, Varon S. 1986. Lowry protein assay using an automatic microtiter plate spectrophotometer. Anal. Biochem. 153:262-266. (Pubitemid 16055103)
37. Whitmore L, Wallace BA. 2008. Protein secondary structure analyses from circular dichroism spectroscopy: methods and reference databases. Biopolymers 89:392-400.
38. Compton LA, Johnson WC, Jr. 1986. Analysis of protein circular dichroism spectra for secondary structure using a simple matrix multiplication. Anal. Biochem. 155:155-167. (Pubitemid 16034476)
39. Darrieux M, Moreno AT, Ferreira DM, Pimenta FC, de Andrade AL, Lopes AP, Leite LC, Miyaji EN. 2008. Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades. J. Med. Microbiol. 57:273-278. (Pubitemid 351358529)
40. Goulart C, Darrieux M, Rodriguez D, Pimenta FC, Brandileone MC, de Andrade AL, Leite LC. 2011. Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells. Vaccine 29:1634-1642.
41. Anderson P, Pichichero ME, Insel RA. 1985. Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197. J. Clin. Invest. 76:52-59. (Pubitemid 15240416)
42. Lee CH, Kuo WC, Beri S, Kapre S, Joshi JS, Bouveret N, LaForce FM, Frasch CE. 2009. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine 27:726-732.
43. Fairchild RL, Braley-Mullen H. 1983. Characterization of the murine immune response to type 6 pneumococcal polysaccharide. Infect. Immun. 39:615-622. (Pubitemid 13188338)
44. Chu RS, McCool T, Greenspan NS, Schreiber JR, Harding CV. 2000. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies. Infect. Immun. 68:1450-1456. (Pubitemid 30108543)
45. Gilles MA, Hudson AQ, Borders CL, Jr. 1990. Stability of water-soluble carbodiimides in aqueous solution. Anal. Biochem. 184:244-248. (Pubitemid 20055618)
46. Farkas P, Bystricky S. 2007. Efficient activation of carboxyl polysaccharides for the preparation of conjugates. Carbohydr. Polymers 68:187-190. (Pubitemid 46204871)
47. Schlottmann SA, Jain N, Chirmule N, Esser MT. 2006. A novel chemistry for conjugating pneumococcal polysaccharides to Luminex microspheres. J. Immunol. Methods 309:75-85. (Pubitemid 43190803)
48. Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène JP, Lommel P, Dieussaert I, Schuerman L. 2009. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr. Infect. Dis. J. 28(4 Suppl):S66-S76.
49. McDaniel LS, Ralph BA, McDaniel DO, Briles DE. 1994. Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microb. Pathog. 17:323-337.
50. McDaniel LS, Sheffield JS, Swiatlo E, Yother J, Crain MJ, Briles DE. 1992. Molecular localization of variable and conserved regions of pspA and identification of additional pspA homologous sequences in Streptococcus pneumoniae. Microb. Pathog. 13:261-269.
51. Daniels CC, Coan P, King J, Hale J, Benton KA, Briles DE, Hollingshead SK. 2010. The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis. Infect. Immun. 78:2163-2172.
52. Csordas FC, Perciani CT, Darrieux M, Goncalves VM, Cabrera-Crespo J, Takagi M, Takagi M, Sbrogio-Almeida ME, Leite LC, Tanizaki MM. 2008. Protection induced by pneumococcal surface protein A (PspA) is enhanced by conjugation to a Streptococcus pneumoniae capsular polysaccharide. Vaccine 26:2925-2929.